<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8222">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885104</url>
  </required_header>
  <id_info>
    <org_study_id>8114-003</org_study_id>
    <secondary_id>CL2012-13</secondary_id>
    <nct_id>NCT01885104</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)</brief_title>
  <official_title>Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG
      3350 solution concentrate to oral ingestion of a placebo solution concentrate, in
      participants with constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with inflammation of the oral mucosa</measure>
    <time_frame>Up to 17 days after start of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with inflammation of the esophageal mucosa</measure>
    <time_frame>Up to 17 days after start of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>PEG 3350</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol (PEG 3350)</intervention_name>
    <arm_group_label>PEG 3350</arm_group_label>
    <other_name>MiraLAX Solution Concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ambulatory male or female with no history or current evidence of other conditions or
             abnormalities that would affect study results or interfere with participation for
             full duration of study

          -  meets diagnostic criteria for functional constipation. This includes loose stools
             that are rarely present without the use of laxatives and 2 or more of the following:
             straining during at least 25% of defecations; lumpy or hard stools in at least 25% of
             defecations; sensation of incomplete evacuation for at least 25% of defecations;
             sensation of anorectal obstruction/blockage for at least 25% of defecations; manual
             maneuvers to facilitate at least 25% of defecations [e.g., digital evacuation,
             support of the pelvic floor]; and fewer than 3 defecations per week. Criteria for
             functional constipation must be fulfilled for last 3 months, with symptom onset at
             least 6 months prior to diagnosis.

          -  continuous or recurrent symptoms for at least 3 months of: abdominal pain or
             discomfort, relieved with defecation, or associated with a change in frequency or
             consistency of stool, and an irregular pattern of defecation at least 25% of the time
             with 3 or more of the following: altered stool frequency, altered stool form (hard or
             loose/watery), altered stool passage (straining or urgency, feeling of incomplete
             evacuation), passage of mucus, and bloating or abdominal distension

          -  agrees to not use laxatives other than study medication for the duration of the study
             period

          -  agrees to not use disallowed concomitant medications for the duration of the study

          -  agrees to maintain a similar diet and level of activity from the period of the
             Screening Visit through End of Study

          -  individuals of reproductive potential must agree to remain abstinent or use (or have
             their partner use) 2 acceptable methods of birth control and until 2 weeks after the
             last dose of study drug in the last treatment period. Acceptable methods of birth
             control include: intrauterine device (IUD), diaphragm with spermicide, contraceptive
             sponge, condom, or vasectomy.

        Exclusion Criteria:

          -  abnormal baseline endoscopy and/or an oral exam

          -  baseline oral exam showing evidence of oral lesions, such as herpes labialis or
             aphthous stomatitis, or known self-reported history or current periodontal gum
             disease

          -  history of impaired swallowing or difficulties swallowing foods and liquids

          -  known, history of, or suspected gastrointenstinal disease, including bowel
             perforation, obstruction, fecal impaction; irritable bowel syndrome (IBS), delayed
             gastric emptying, gastroparesis, gastroesophageal reflux disease (GERD), gastritis or
             peptic ulcer disease (PUD), dehydration, inflammatory bowel disease, bowel resection,
             anal fistulas/fissures, colostomy, etc.

          -  severe or unexplained abdominal pain

          -  history of or current alcohol or drug abuse

          -  history of malignancy â‰¤5 years prior to signing the informed consent, except for
             adequately treated basal cell and/or squamous cell skin cancer or in situ cervical
             cancer

          -  history of psychiatric illness requiring medications or hospitalization within the
             previous 12 months

          -  history of concurrent illness that required hospitalization within 4 weeks prior to
             Day -1 of the study

          -  allergies or allergic reactions or intolerance to any of the products used in study

          -  any degree of renal impairment

          -  major surgery or clinically significant illness within 4 weeks prior to Day -1 of
             Visit 1

          -  current  or recent (within the past 30 days of signing informed consent)
             participation in a study with an investigational compound or device

          -  refusal to agree not to donate eggs or sperm upon the first study drug administration
             and thereafter through 90 days after the last study drug administration

          -  individual is an employee or family member of an employee of the sponsor or clinical
             unit where study will be conducted
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>June 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
